Therapeutics in Rheumatology

1. Front Matter

   Pages i-xiv

   PDF

2. Pharmacological and therapeutic principles

   1. Front Matter

      Pages 1-2

      PDF

   2. The pharmacological basis of antirheumatic drug therapy

      • N. D. Hall

      Pages 3-48

   3. Pharmacokinetics

      • Allister J. Taggart, Dean W. G. Harron

      Pages 49-86

   4. Drug interactions

      • M. C. L’E. Orme

      Pages 87-126

   5. Adverse reactions

      • A. Rushton

      Pages 127-147

   6. Evaluation of drug response

      • R. Madhok, H. A. Capell

      Pages 148-179

3. The rheumatological pharmacopoeia

   1. Front Matter

      Pages 181-181

      PDF

   2. Simple analgesics and pain

      • D. E. Caughey

      Pages 183-205

   3. Non-steroidal anti-inflammatory drugs

      • David M. Grennan, Carol Higham

      Pages 206-241

   4. Corticosteroids in rheumatic diseases

      • Vera C. M. Neumann

      Pages 242-260

   5. Slow-acting antirheumatoid drugs

      • H. Berry

      Pages 261-294

   6. New drugs and experimental progress

      • V. Wright

      Pages 295-317

4. Clinical applications and implications

   1. Front Matter

      Pages 319-320

      PDF

   2. Rheumatoid arthritis

      • L. P. J. Holt

      Pages 321-357

   3. The spondarthritides

      • Ian Haslock

      Pages 358-377

   4. Osteoarthrosis, spinal degenerative disease and other back pain syndromes

      • Sunil P. Liyanage

      Pages 378-413

   5. Gout and other crystal-deposition disorders

      • J. M. H. Moll

      Pages 414-440

   6. Miscellanea and rarities

      • F. Dudley Hart

      Pages 441-478

   7. Drug-induced syndromes and drug toxicity

      • B. L. Hazleman

      Pages 479-513

This book is about the drugs used in the treatment and management of rheumatic disorders. The term 'therapeutics' used in the title is intended to mirror the relevance of drugs in the widest sense of the word. Thus, general principles underlying pharmaceutical and pharmacological study have been included together with more clinical matters concerned with applying specific rheumatic problems. The need for another work on rheumatological drugs in itself, as opposed to the different approach intended, was prompted by the ever continuing and bewildering plethora of antirheumatic drugs flooding the market at present. We believe that such a burgeoning of new preparations is welcome in an era when in general there are still no 'cures' available. Moreover, we also feel that a continued update of this rapidly advancing field is essential, not only for its own sake, but also to place it in perspective with itself and with neighbouring fields.

• Arthritis
• pain
• rheumatic diseases
• rheumatoid arthritis
• rheumatology

• Sheffield Centre for Rheumatic Diseases, Nether Edge Hospital, Sheffield, UK

  J. M. H. Moll

• University of Sheffield, UK

  J. M. H. Moll

• General Infirmary at Leeds, University Department of Medicine, UK

  H. A. Bird

• General Infirmary at Leeds and Royal Bath Hospital, Harrogate, UK

  H. A. Bird

• Clinical Research Department, Imperial Chemical Industries PLC, Pharmaceuticals Division, Macclesfield, UK

  A. Rushton

Policies and ethics